Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Advanced Extrapulmonary Neuroendocrine Carcinoma: a Prospective, Multicenter, Single-arm, Phase 2 Clinical Study
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Tucidinostat (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 02 Nov 2021 Status changed from not yet recruiting to recruiting.
- 18 Oct 2021 New trial record